Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-Year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

Breast Cancer Research and Treatment

Volumn 132, Issue 2, 2012, Pages 609-619

  Gogas, Helen ^a   Dafni, Urania ^a   Karina, Maria ^b   Papadimitriou, Christos ^c   Batistatou, Anna ^d   Bobos, Mattheos ^b   Kalofonos, Haralabos P ^e   Eleftheraki, Anastasia G ^f   Timotheadou, Eleni ^b   Bafaloukos, Dimitrios ^g   Christodoulou, Christos ^g   Markopoulos, Christos ^a   Briasoulis, Evangelos ^d   Papakostas, Pavlos ^h   Samantas, Epaminontas ⁱ   Kosmidis, Paris ^j   Stathopoulos, George P ^k   Karanikiotis, Charisios ^l   Pectasides, Dimitrios ^h   Dimopoulos, Meletios A ^c   Fountzilas, George ^b   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f Hellenic Cooperative Oncology Group   (Greece)

^g METROPOLITAN HOSPITAL   (Greece)

^h HIPPOKRATION HOSPITAL   (Greece)

ⁱ AGII ANARGIRI CANCER HOSPITAL   (Greece)

^j HYGEIA HOSPITAL   (Greece)

^k HENRY DUNANT HOSPITAL   (Greece)

^l 424 General Army Hospital   (Greece)

more..

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Dose dense

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; GREECE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859099698     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1913-4     Document Type: Article

References (41)

1. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792 (Pubitemid 41549890)
2. Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6(Suppl 3):30-35
3. Trudeaue M, Charbonneau F, Gelmon K et al (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886-898 (Pubitemid 41614801)
4. Bonadonna G, Zambetti M, Valagussa P (1995) Sequential oralternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542-547
5. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983 (Pubitemid 46594124)
6. Hudis C, Seidman A, Baselga J et al (1999) Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 17:93-100 (Pubitemid 29022382)
7. Founzilas G, Nicolaides C, Aravantinos G et al (1998) Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and 10 positive axillary lymph nodes. A feasibility study. Oncology 55:508-512 (Pubitemid 28479106)
8. Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Cancer Treat Res 70:163-169 (Pubitemid 16140378)
9. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer; first report of Intergroup Trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431-1439 (Pubitemid 46594092)
10. Fountzilas G, Dafni U, Gogas H et al (2007) Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized Phase III trial HE 10/00. Ann Oncol 19:853-860 (Pubitemid 351649185)
11. Coombes RC, Hall E, Gibson LJ et al (2004) Intergroup Exemestane Study. Arandomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092 (Pubitemid 38298988)
12. Fountzilas G, Skarlos D, Dafni U et al (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16:1762-1771 (Pubitemid 41631238)
13. Moher D (1998) CONSORT: anevolving tool to help improve the quality of reports of randomized controlled trials. JAMA 279:1489-1491
14. Hudis C, Fornier M, Riccio L et al (1999) 5-Year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 17:118-1126
15. Hryniuk W (2001) Dosage parameters inchemotherapy of breast cancer. Breast Dis 14:21-30
16. Piccart-Gebhart MJ (2003) Mathematics and Oncology: amatch for life? J Clin Oncol 21:1425-1428
17. Trudeau ME (2001) Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study. Oncology (Williston Park) 5(Suppl. 7):7-13
18. Moebus V, Jackisch Ch, Luek HJ et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28:2874-2880
19. Hudis C, Citron M, Berry D et al (2005) Five year follow-up of INT C9741: Dose dense chemotherapy is safe and effective. Breast Cancer Res Treat 94:S20 (suppl: abstr 41)
20. Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992
21. Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671 (Pubitemid 351549913)
22. Mamounas EP, Bryant J, Lembersky BC et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer. Results from NSABPB28. J Clin Oncol 23:3686-3696
23. Fisher B, Anderson S, Wickerham DL et al (1996) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer. Findings from national surgical adjuvant breast and bowel project B-22. J Clin Oncol 15:1858-1869 (Pubitemid 27209515)
24. Fisher B, Anderson S, DeCillis A et al (1999) Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Finding from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388 (Pubitemid 29517904)
25. Bonilla L, Ben-Aharon I, Vidal L et al (2010) Dose-Dense chemotherapy innonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. JNCI 24:1845-1854
26. Venturini M, Del Mastro L, Aitini E et al (2005) Dose-dense adjuvant chemotherapy in early breast cancer patients. Results from a randomized trial. J Natl Cancer Inst 97:1724-1733 (Pubitemid 41782282)
27. Levine MN, Pritchard KI, Bramwell VHC et al (2005) Randomized trial comparing cyclophosphamide, epirubicin and fluorouracil with cyclophosphamide, methotrexate and flouorouracil in premenopausal women with node-positive breast cancer. Update of National Cancer Institute of Canada Clinical Trial Group Trial MA5. J Clin Oncol 23:5166-5170 (Pubitemid 46224025)
28. Bonneterre J, Roche H, Kerbrat P et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10 year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686-2693 (Pubitemid 46179458)
29. Linden HM, Haskell CM, Green SJ et al (2007) Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol 25(6):656-661 (Pubitemid 350002920)
30. Burnell M, Levine MN, Chapman Jw et al (2010) Cyclophosphaimide, epirubicin and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28:77-82
31. Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response topaclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506 (Pubitemid 47572635)
32. Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667
33. Gluz O, Nitz UA, Harbeck N et al (2008) Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 19:861-870 (Pubitemid 351649186)
34. Eiermann W, Pienkowski T, Crown J (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29:3877-3884
35. Piedbois P, Serin D, Priou F et al (2007) Dose-dense adjuvant chemotherapy innode-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 18:52-57 (Pubitemid 46152499)
36. Gluck S (2005) Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 10:780-791
37. Praga C, Bergh J, Biss J et al (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23:4179-4191 (Pubitemid 46211324)
38. Burstein HJ, Parker LM, Keshaviah A et al (2005) Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 23:8340-8347
39. Smith TJ, Khatcheressian J, Lyman GH et al (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:1-19
40. Hershman D, Neugut Al, Jacobson JS et al (2007) Acute myeloid leukemia ormyelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196-205
41. Chau D (2011) The End of an era: shall we move forward? JCO 3849-3851